A study to verify the acute therapeutic effect of mepolizumab for eosinophilicpolyangiitis granulomatosis (EGPA) neuropathy(A Prospective Observational Study)

Takeshita Yukio0 个研究点目标入组 20 人开始时间: 2024年2月1日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1) Patients =<30 day after onset of EGPA neuropathy.
•2) Patients who treated with steroid-pulse therapy (3 days) during the acute phase of EGPA neuropathy and shown no complete remission in EGPA neuropathy.
•3) Patients who meet the American Society of Rheumatology EGPA classification criteria or American College of Rheumatology/European League Against Rheumatism EGPA classification criteria.
•4) Patients aged 20 years or older at the time of onset of EGPA neuropathy.
•5) Regardless of gender.
•6) Patients who gave informed consent to participate in the study by the patient or the legally acceptable
•representative after receiving adequate explanation for their participation in the study.

•1) Patients being treated with mepolizumab
•2) Patients who received steroid-pulse therapy (3 days) in the acute phase of EGPA neuropathy and had complete EGPA neuropaty resolution.
•3) Life-threatening patients
•4) Patients who were judged inappropriate by principal investigator

发起方

Takeshita Yukio